Collaborative arrangement profit sharing percentage.

No definition available.

Name:	plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	plx_MilestonePayment
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognized over designated period.

+ References

No definition available.

+ Details

Name:	plx_RevenueRecognizedOverDesignatedPeriod
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value of the entity's equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name:	us-gaap_EquityFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value of asset after deduction of liability.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueNetAssetLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_CollaborationOperationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=plx_ScenarioTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=plx_UponFDAApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

AGREEMENTS WITH PFIZER (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Oct. 31, 2015	Nov. 30, 2009	Dec. 31, 2015	Dec. 31, 2012	Oct. 12, 2015	Dec. 31, 2014
Revenue Recognized Over Designated Period			$ 4.6
Proceeds from Collaborators		$ 60.0
Milestone Payment		$ 25.0
Protalix Bio Therapeutics Incorporation [Member]
Collaborative Arrangement Profit Share Percentage		40.00%
Collaboration Operation [Member]
Accrued Liabilities					$ 4.3	$ 7.1
Pfizer [Member]
Stock Issued During Period, Shares, New Issues	5,649,079
Debt Instrument, Face Amount	$ 4.3
Fair Value, Net Asset (Liability), Total	46.0
Equity, Fair Value Disclosure, Total	6.1
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	$ 39.9
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Proceeds from Collaborators		$ 5.0
Upon FDAApproval [Member]
Milestone Payment				$ 25.0